https://uc2288inhibitor.com/ef....fect-of-standard-pai
OUTCOMES The safety population comprised 1,073 patients (placebo [n=412], lumateperone 42mg [n=406], risperidone [n=255]). TEAEs that occurred within the lumateperone 42mg group at a level of ≥5% and twice placebo had been somnolence/sedation (24.1% vs 10.0%) and dry mouth (5.9% vshizophrenia. FINANCING ACKNOWLEDGEMENTS sustained by funding from Intra-Cellular Therapies, Inc.STUDY OBJECTIVES Depression is the leading reason for impairment internationally, with fewer than 50percent
Like
Comment
Share
